| Reference |
|---|
Alvarez Y, Mancebo C, Alonso S, Montero O, Fern xe1 ndez N, S xe1 nchez Crespo M. Central carbon metabolism exhibits unique characteristics during the handling of fungal patterns by monocyte-derived dendritic cells. Redox Biol. 2024;73:103187 pubmed publisher |
Kumar M, Kumar Singh P, Choudhary S, Silakari O. Hydantoin based dual inhibitors of ALR2 and PARP-1: Design, synthesis, in-vitro and in-vivo evaluation. Bioorg Chem. 2022;129:106108 pubmed publisher |
Koczor C, Haider A, Saville K, Li J, Andrews J, Beiser A, et al. Live Cell Detection of Poly(ADP-Ribose) for Use in Genetic and Genotoxic Compound Screens. Cancers (Basel). 2022;14: pubmed publisher |
Morgan S, Tanizawa H, Caruso L, Hulse M, Kossenkov A, Madzo J, et al. The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity. Nat Commun. 2022;13:187 pubmed publisher |
Ma Y, Chen P, Drisko J, Khabele D, Godwin A, Chen Q. Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer. Oncol Lett. 2020;19:2629-2638 pubmed publisher |
Zhang D, Baldwin P, Leal A, Carapellucci S, Sridhar S, Liby K. A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice. Theranostics. 2019;9:6224-6238 pubmed publisher |
Riches L, Trinidad A, Hughes G, Jones G, Hughes A, Thomason A, et al. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically. Mol Cancer Ther. 2020;19:13-25 pubmed publisher |
Matveeva E, Mathbout L, Fondufe Mittendorf Y. PARP1 is a versatile factor in the regulation of mRNA stability and decay. Sci Rep. 2019;9:3722 pubmed publisher |
Matveeva E, Al Tinawi Q, Rouchka E, Fondufe Mittendorf Y. Coupling of PARP1-mediated chromatin structural changes to transcriptional RNA polymerase II elongation and cotranscriptional splicing. Epigenetics Chromatin. 2019;12:15 pubmed publisher |
Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, et al. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget. 2018;9:37080-37096 pubmed publisher |
Martin K, Lupey L, Tempera I. Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1. J Virol. 2016;90:8520-30 pubmed publisher |
Rodler E, Kurland B, Griffin M, Gralow J, Porter P, Yeh R, et al. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res. 2016;22:2855-64 pubmed publisher |
Martin K, Cesaroni M, Denny M, Lupey L, Tempera I. Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2. Mol Cell Biol. 2015;35:3934-44 pubmed publisher |
Karginova O, Siegel M, Van Swearingen A, Deal A, Adamo B, Sambade M, et al. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Mol Cancer Ther. 2015;14:920-30 pubmed publisher |
Lee J, Hays J, Annunziata C, Noonan A, Minasian L, Zujewski J, et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst. 2014;106:dju089 pubmed publisher |
Kinders R, Ferry Galow K, Wang L, Srivastava A, Ji J, Parchment R. Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations. Clin Cancer Res. 2014;20:2578-86 pubmed publisher |
Horton J, Stefanick D, Prasad R, Gassman N, Kedar P, Wilson S. Base excision repair defects invoke hypersensitivity to PARP inhibition. Mol Cancer Res. 2014;12:1128-39 pubmed publisher |
Janzen D, Paik D, Rosales M, Yep B, Cheng D, Witte O, et al. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo. Mol Cancer Ther. 2013;12:2917-28 pubmed publisher |
Cardnell R, Feng Y, Diao L, Fan Y, Masrorpour F, Wang J, et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013;19:6322-8 pubmed publisher |
Horton J, Wilson S. Predicting enhanced cell killing through PARP inhibition. Mol Cancer Res. 2013;11:13-8 pubmed publisher |
Heitz F, du Bois A, Rochon J, Scheil Bertram S, Hils R, Fisseler Eckhoff A, et al. Requirements to assess feasibility of phase 0 trials during major abdominal surgery: variability of PARP activity. Clin Cancer Res. 2012;18:2632-7 pubmed publisher |
